BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Therapeutics announced the inclusion of Penn Medicine’s Abramson Cancer Center as a clinical trial location for its ongoing pivotal Phase 3 study evaluating Bria-IMT, an immunotherapy regimen for advanced breast cancer. This expansion reflects increased interest from leading cancer centers and sustained enrollment momentum, with the trial …